What the trial was testing
The trial enrolled 247 patients with type 2 diabetes. The study was sponsored by Novo Nordisk A/S and tracked outcomes across the full group of patients who matched the trial's eligibility profile.
It was initial testing (phase 2). Trials at this stage are designed to produce evidence regulators and physicians can act on — not just observations to follow up later.
What the results showed
Weekly insulin lowered A1C by 1.33 points — matching daily insulin's 1.15-point drop.
The New England journal of medicine · 2020 · NCT03751657
These findings — that weekly insulin lowered blood sugar as much as daily insulin — were published in the The New England journal of medicine and represent the headline result of the study.
Researchers tracked outcomes across 247 patients enrolled in the trial. The result was consistent enough across the group that the team felt confident reporting it.
What this means for patients
For patients with type 2 diabetes, this result changes the calculus on what to ask their care team about. Whether it changes day-to-day care depends on factors like disease subtype, prior treatments, and where the patient is in their care journey.
What you can do now
If you're starting insulin for type 2 diabetes, this weekly shot could be a simpler option than daily injections. This was a mid-stage study, so the weekly insulin isn't FDA-approved yet. Talk to your doctor about whether starting with daily insulin now makes sense, or if waiting for this weekly option might work for you.
Eligibility for the treatments mentioned above depends on specific test results and clinical history. Bring this summary, the trial name, and your most recent labs or pathology report to your next visit.
Open type 2 diabetes trials
Circadian Intervention to Improve Cardiometabolic Health
The overall goal is to examine the efficacy of a circadian intervention in people with overweight and obesity and habitual short sleep duration (HSSD). Participants will undergo a randomized controlled trial, with circadian intervention and control (healthy lifestyle) groups. The circadian intervention is designed to reduce nighttime light exposure and after-dinner snack food intake. Alternatively, the control group will receive basic health information (e.g., physical activity, goal setting, and nutrition when eating out).
Pancreatic Islet Transplantation Into the Anterior Chamber of the Eye
The intervention in this trial is intraocular islet transplantation. A single dose of 1000 - 3000 Islet Equivalents (IEQ)/kg recipient body weight (BW) will be infused into the anterior chamber of the eye through a self-sealing incision in the peripheral cornea. The procedure is projected to take approximately 20-30 minutes. Transplant recipients in this study will receive localized maintenance immunosuppression via topical application of eye-drops.